Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting

Wednesday, December 3, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., Dec. 3 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,will host a webcast and conference call on, Monday, December 8, 2008, at 2:00p.m. Eastern Time (8:00 p.m. Central European Time) to discuss theblinatumomab data that were presented at the American Society of Hematology(ASH) meeting.

To access the webcast and view the PowerPoint presentation, please log onto: http://webcasts.micromet-inc.com. To participate in the conference call,dial 866-700-7441 (U.S.) or 617-213-8839 (international), passcode: 39298646.

A replay of the call will be available from 4:00 p.m. Eastern Time onDecember 8, 2008 (10:00 p.m. Central European Time) through Monday, December22, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888(international), passcode: 27748310.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company withoffices in Bethesda, Maryland and Munich, Germany. The Company is developingnovel, proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. The Company uses its proprietary BiTE(R) antibodyplatform to create a new class of antibodies that specifically activate Tcells from the patient's own immune system to eliminate cancer cells or otherdisease-related cells. Four of the Company's antibodies are currently inclinical trials, with the remainder of its product pipeline in preclinicaldevelopment. The Company's lead program is a BiTE antibody known asblinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment ofpatients with acute lymphoblastic leukemia and a phase 1 clinical trial forthe treatment of patients with non-Hodgkin's lymphoma. Micromet is developingblinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc.Micromet's second BiTE antibody in clinical development is MT110, whichtargets the epithelial cell adhesion molecule (EpCAM). The Company owns allrights to MT110, which is currently in a phase 1 clinical trial for thetreatment of patients with solid tumors. The Company's third clinical stageantibody is adecatumumab, also known as MT201, a conventional human monoclonalantibody that targets EpCAM-expressing solid tumors. Micromet is developingadecatumumab in collaboration with Merck Serono in a phase 1b clinical trialevaluating adecatumumab in combination with docetaxel for the treatment ofpatients with metastatic breast cancer. Micromet has licensed a fourthclinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is beingdeveloped in a phase 1 clinical trial for the treatment of patients withcancer. The Company's preclinical programs include MT203, which is beingdeveloped in collaboration with Nycomed. MT203 is a traditional human antibodyneutralizing the activity of granulocyte/macrophage colony stimulating factor(GM-CSF), which has potential applications in the treatment of inflammatoryand autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiplesclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR andMCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involverisks and uncertainties that could cause actual results to be materiallydifferent from historical results or from any future results expressed orimplied by such forward-looking statements. These forward-looking statementsinclude statements regarding the efficacy and intended utilization of ourproduct candidates and the development of our BiTE antibody technology. Youare urged to consider statements that include the words "may," "potential," orthe negative of those words or other similar words to be uncertain andforward-looking. Factors that may cause actual results to differ materiallyfrom any future results expressed or implied by any forward-looking statementsinclude the risk that product candidates that appeared promising in earlyresearch, preclinical studies or clinical trials do not demonstrate safetyand/or efficacy in subsequent clinical trials, the risk that encouragingresults from early research, preclinical studies or clinical trials may not beconfirmed upon further analysis of the detailed results of such research,preclinical study or clinical trial, and the risk that additional informationrelating to the safety, efficacy or tolerability of our product candidates maybe discovered upon further analysis of preclinical or clinical trial data.These factors and others are more fully discussed in Micromet's QuarterlyReport on Form 10-Q for the fiscal quarter ended September 30, 2008, filedwith the SEC on November 6, 2008, as well as other filings by the company withthe SEC.

Any forward-looking statements are made pursuant to Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities ExchangeAct of 1934, as amended, and, as such, speak only as of the date made.Micromet, Inc. undertakes no obligation to publicly update any forward-lookingstatements, whether as a result of new information, future events orotherwise.

SOURCE Micromet, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store